




Today, biotechnology is one of the most dynamically growing areas of science 
and technology. Potential benefits from its use can be found in the following fields: 
healthcare, development of new materials and alternative fuels, agriculture, food 
industry, environmental protection, etc. 
Biotechnology is one of the leading trends in the 21st century due to its wide 
scope of application and huge space for further development. It is safe to say that 
conducting research & development (R&D) in the field of biotechnology, providing 
financial support to biotech companies and ensuring public access to their products are 
key tasks for any country in the world.  
At the moment, the Russian Federation is not among the world leaders in the 
biotechnology market, but this situation may change in the future. Biopharmaceutics is 
considered one of the most developed biotechnological industries in our country, the 
most promising areas are bioenergy, industrial, food and environmental biotechnology 
[2]. In this article the main trends in the development of the biotechnology market in 
Russia and in the world are examined. 
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C. elegans is one of the best and most preferred model system to study 





disease (PD) [1]. To this day, the underlying mechanism of neurodegenerative 
disorders are not well understood. It is necessary to obtain knowledge regarding the 
fundamental mechanisms and causes behind specific neuronal deaths [1–3]. The 
present study focuses on conducting a systematic review of literature on the application 
of C. elegans as a model to investigate different neurodegenerative diseases and to note 
the recent findings regarding the underlying pathogenesis of Alzheimer’s disease (AD) 
and Parkinson’s disease (PD). Using C. elegans, a parasite as a model system to study 
ND demands the combination of different domains and expertise of Neuroscience, 
molecular science and Nematology [5, 6]. So, it involves multidisciplinary approach 
which focuses on solving the issues for society (old population suffering from ND). 
A search was conducted in PubMed and Scopus for the articles published from 
December 1993 up to January 2019 using the keywords such as C. elegans, model 
system, Alzheimer models, Parkinson models, nematode models and 
neurodegenerative disease models. 110 documents in Scopus and 42 documents in 
PubMed were found to be relevant to this study. The articles were screened based on 
the title, abstract and full text.  
Ultimately, the outcome of this review suggests that the C. elegans is one of the 
most preferred model for the investigation of several neurodegenerative diseases due 
to its high efficiency. As a result, finding novel therapeutics for treating these 
devastating diseases may soon become a reality and may lead to its eventual eradication 
in near future [7, 8]. 
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